The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
May 13th 2024Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.
Lung Cancer Screening Dramatically Increases Long-term Survival Rate
Diagnosing early-stage lung cancer with low-dose computed tomography screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.
The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.
New RNA-based Therapy Combats Melanoma in Mouse Models
Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.
Mount Sinai Launches Clinic to Help Breast Cancer Patients in Need of Legal Services
The Mount Sinai Medical Legal Partnership, which provides legal aid to Mount Sinai Health System patients in need, has launched a clinic to help breast cancer patients navigate legal issues that arise due to their diagnoses.
Adding Immunotherapy to Chemotherapy Regimen Improves Survival in Metastatic Bladder Cancer Patients
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.